Pharmaceuticals News

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing...

CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and...

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the...

PORTLAND, Maine, Oct. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets...

 Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with...

Oncolytics extends pelareorep patent protection into the late 2040s while planning new IP for next-generation pelareorep.

– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – –...

        PRESS RELEASE AB SCIENCE WILL HOLD A WEB CONFERENCE ON WEDNESDAY, OCTOBER 14, FROM 6:00 P.M. TO 7:30 P.M. Paris, October 12, 2026, 6:00 p.m. AB Science SA (Euronext - FR0010557264 - AB)...

        COMMUNIQUÉ DE PRESSE AB SCIENCE TIENDRA UNE WEB CONFÉRENCE LE MERCREDI 14 OCTOBRE DE 18H A 19H30 Paris, 12 octobre 2026, 18h AB Science SA (Euronext - FR0010557264 - AB) tiendra une web...